Lobbying Filing Details

Total Spending

$1,200,000

Activities

7

Lobbyists

5

Gov't Entities

22

Filing Information
Filing UUID:
ab61f2b1-d8bc-4913-a5ae-fdfce0c8fbe2
Type:
Q2 - 2nd Quarter - Report
Period:
2026 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 16, 2026 at 3:05 PM
Income:
$0
Expenses:
$1,200,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Samantha Ventimiglia
Registrant
VERTEX PHARMACEUTICALS INCORPORATED

Global biotechnology company

Boston, Massachusetts
Client
VERTEX PHARMACEUTICALS INCORPORATED
Massachusetts, United States of America
Lobbying Activities (7)
Activity 1
Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.

Lobbyists (5)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
  • KYLE HILL
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Defense

Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.

Lobbyists (3)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
District of Columbia

Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.

Lobbyists (3)
  • MATTHEW O SCHUMAKER
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Commerce, Dept of (DOC)
Activity 4
Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Lobbyists (5)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
  • KYLE HILL
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 5
Medicare/Medicaid

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.

Lobbyists (5)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
  • KYLE HILL
Government Entities (9)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Vice President of the U.S.
  • White House Office
  • ... and 4 more
Activity 6
Taxation/Internal Revenue Code

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.

Lobbyists (1)
  • SWARNA VALLURUPALLI
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 7
Veterans

Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).

Lobbyists (5)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
  • KYLE HILL
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.